All In Biotech

Drug Trial Radar · NCT01283516

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Last checked: Nov 20, 2026Latest source record: Mar 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

304

Actual

Start

Jan 24, 2011

Primary completion

May 3, 2016

Study completion May 3, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).

Conditions

  • Tumors Characterized by Genetic Abnormalities of ALK

Interventions

  • LDK378Drug

    LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: 33 months

Locations

21 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Colorado School of Medicine Colorado Univ

    Aurora, Colorado

  • Massachusetts General Hospital Mass General

    Boston, Massachusetts

  • Memorial Sloan Kettering MSK

    New York, New York

  • Fox Chase Cancer Center Fox Chase Cancer (2)

    Philadelphia, Pennsylvania

  • University of Utah / Huntsman Cancer Institute Huntsman

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, Korea, South Korea

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Leicester, United Kingdom

  • Novartis Investigative Site

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.